<DOC>
	<DOCNO>NCT02222480</DOCNO>
	<brief_summary>A 2-Week , Randomized , Double-Blind , Parallel , Placebo-Controlled Study Evaluate Efficacy , Tolerability , Pharmacokinetic-Pharmacodynamic Relationship Fimasartan Combination Hydrochlorothiazide Patients Mild Moderate Hypertension</brief_summary>
	<brief_title>A Clinical Trial Evaluate Efficacy , Tolerability , Pharmacokinetic-Pharmacodynamic Relationship Fimasartan/Hydrochlorothiazide</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>1 . Male female subject childbearing potential 1970 year age 2 . Mean clinicmeasured sit DBP ( siDBP ) 90109 mmHg mean clinicmeasured sit SBP ( siSBP ) 140179 mmHg ≥1week washout prior antihypertensive medication ( washout need antihypertensive medication ) difference ≤10 mmHg sit DBP runin 3 . Subjects agree participate study give write informed consent 4 . Subjects consider understand study , cooperative , able followedup end study 1 . Severe hypertension , i.e. , mean siDBP ≥110 mmHg mean siSBP ≥180 mmHg 2 . Orthostatic hypotension clinically significant sign symptom 3 . Secondary hypertension 4 . Not able stop administration antihypertensive medication study drug ( i.e. , fimasartan hydrochlorothiazide ) throughout entire study period 5 . Clinically significant abnormal laboratory test result , e.g. , serum creatinine &gt; 1.5 time upper limit normal , AST , ALT &gt; 2 time upper limit normal 6 . Conditions may affect absorption , distribution , metabolism , excretion study drug 7 . Severe insulindependent uncontrolled diabetes mellitus ( HbA1c &gt; 9 % , increase dose oral hypoglycemic agent within 12 week screen , active insulin treatment screen ) 8 . Severe cardiovascular disease within 6 month screen include ischemic heart disease , peripheral vascular disease , significant ventricular tachycardia , atrial fibrillation , atrial flutter significant arrhythmia , hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , hemodynamically significant aortic valve mitral valve disease , severe cerebrovascular disease 9 . History percutaneous transluminal coronary angiography coronary artery bypass graft 10 . Chronic debilitate disease , autoimmune disease , connective tissue disease 11 . Positive serum hepatitis B surface antigen , antihepatitis C virus antibody , antiHIV antibody 12 . History evidence alcohol drug abuse within 2 year 13 . Known allergic reaction angiotensin receptor blocker 14 . Chronic inflammation disease require chronic antiinflammation therapy 15 . Women childbearing potential without contraceptive measure breastfeed mother 16 . Prior participation clinical trial investigational product within 12 week screen 17 . Serum potassium &lt; 3.5 mmol/L &gt; 5.5 mmol/L time study period 18 . Depletion sodium ion body fluid , correct easily study period 19 . Evidence hereditary disease , include galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption . 20 . Considered unsuitable participate study discretion principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Patients</keyword>
	<keyword>mild</keyword>
	<keyword>moderate</keyword>
	<keyword>essential</keyword>
</DOC>